Lube News: Divine 9 Helps Prevent HPV!

Can a lubricant actually prevent HPV? Promising new research from the National Cancer Institute suggests it can.


Divine 9 Personal Lubricants

Breaking Lube News: This is BIG.


Our Divine 9 Personal Lubricant goes above and beyond simple lubrication – It may also be a brand-new weapon in HPV prevention. Why? Carrageenan. This extract from red seaweed not only has the ability to replicate the body’s own natural fluids, making it a safe alternative to glycerine-based lubricants, but has also been shown to be a potent inhibitor of human papillomavirus infection.


The World Health Organization lists cervical cancer as the second-leading cause of female cancer fatalities worldwide, accounting for more than 250,000 deaths each year. More than 85 percent of these cases occur in developing countries. In addition to the cancer concerns, certain types of HPV cause genital warts on both men and women.


To date, the options to fight the spread of HPV have been limited. However, A research team at the National Cancer Institute has conducted both in vitro (laboratory) and in vivo (animal) studies and found Divine 9 was highly effective in inhibiting infection rates.


We repeat: The world’s first human clinical trial involving designed to evaluate a topical gel in reducing the risk of genital HPV infections in women has concluded that Divine 9 with CarraShield reduces the likelihood of of HPV infection! Read the research here.


The HPV prevention characteristics of Divine 9 have been previously validated by series of studies at the National Cancer Institute, Albert Einstein College of Medicine and Rutgers University Medical School.


The possibility that Carrageenan-based Divine 9, applied before sexual contact, can block the transmission of HPV would be a breakthrough with worldwide medical significance.


A lubricant that offers comfort AND STD protection? Sounds like a win-win to us!

Divine 9 Water-Based Personal Lubricant



“I’m extremely encouraged by the results of the laboratory studies by Dr. John Schiller’s team at the National Cancer Institute. If the trial is successful, it would mean that women have another option for protecting themselves against HPV, the causative agent for cervical cancer.”

– Dr. Eduardo Franco, Director of the Division of Cancer Epidemiology